An Isogenic Cell Panel Identifies Compounds That Inhibit Proliferation of mTOR-Pathway Addicted Cells by Different Mechanisms
暂无分享,去创建一个
M. Colombi | C. Moroni | U. Regenass | D. Brodbeck | K. Molle | M. Hall | Lorenza Wyder Peters | A. Thiemeyer | A. Knopf | Marie Goxe | P. Guerry | Agnes Knopf
[1] A. Glass,et al. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. , 2012, Anticancer research.
[2] M. Hall,et al. Rapamycin passes the torch: a new generation of mTOR inhibitors , 2011, Nature Reviews Drug Discovery.
[3] Robert L. Sutherland,et al. Cyclin D as a therapeutic target in cancer , 2011, Nature Reviews Cancer.
[4] B. Weigelt,et al. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs , 2011, Oncogene.
[5] A. Giaccia,et al. Harnessing synthetic lethal interactions in anticancer drug discovery , 2011, Nature Reviews Drug Discovery.
[6] A. Ashworth,et al. Genetic Interactions in Cancer Progression and Treatment , 2011, Cell.
[7] C. Schaefer,et al. Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction , 2011, Oncogene.
[8] G. Piazza,et al. A High-Throughput Screen with Isogenic PTEN+/+ and PTEN−/− Cells Identifies CID1340132 as a Novel Compound That Induces Apoptosis in PTEN and PIK3CA Mutant Human Cancer Cells , 2011, Journal of biomolecular screening.
[9] Funda Meric-Bernstam,et al. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. , 2010, Clinical breast cancer.
[10] A. Nakashima,et al. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer , 2010, Oncogene.
[11] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[12] Xiaodong Cheng,et al. Chemical genetic screening of KRAS-based synthetic lethal inhibitors for pancreatic cancer. , 2009, Frontiers in bioscience.
[13] N. Hay,et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. , 2008, Cancer cell.
[14] U. Hellmann-Blumberg,et al. Production of hydrogen peroxide and redox cycling can explain how sanguinarine and chelerythrine induce rapid apoptosis. , 2008, Archives of biochemistry and biophysics.
[15] Robert T Abraham,et al. Targeting the mTOR signaling network in cancer. , 2007, Trends in molecular medicine.
[16] Linxiang Zhao,et al. Ethacrynic acid butyl-ester induces apoptosis in leukemia cells through a hydrogen peroxide mediated pathway independent of glutathione S-transferase P1-1 inhibition. , 2007, Cancer research.
[17] David M Sabatini,et al. Defining the role of mTOR in cancer. , 2007, Cancer cell.
[18] Lirong Diao,et al. PTEN, a general negative regulator of cyclin D expression , 2007, Cell Research.
[19] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.
[20] M. Colombi,et al. Isolation and characterization of dominant and recessive IL-3-independent hematopoietic transformants , 2006, Oncogene.
[21] Jinsong Liu,et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. , 2006, Cancer cell.
[22] V. Stambolic,et al. Localization of Rheb to the endomembrane is critical for its signaling function. , 2006, Biochemical and biophysical research communications.
[23] D. Sabatini,et al. Growing roles for the mTOR pathway. , 2005, Current opinion in cell biology.
[24] P. Beaune,et al. Rapamycin inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression and stability. , 2005, Kidney international.
[25] D. Sabatini,et al. Structure of S6 Kinase 1 Determines whether Raptor-mTOR or Rictor-mTOR Phosphorylates Its Hydrophobic Motif Site*♦ , 2005, Journal of Biological Chemistry.
[26] Stephen S. Taylor,et al. Truncating APC mutations have dominant effects on proliferation, spindle checkpoint control, survival and chromosome stability , 2004, Journal of Cell Science.
[27] William C Hahn,et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. , 2003, Cancer cell.
[28] G. Mills,et al. Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[29] Hong Wu,et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[30] K. Kinzler,et al. Use of isogenic human cancer cells for high-throughput screening and drug discovery , 2001, Nature Biotechnology.
[31] T. Kitamura,et al. Plat-E: an efficient and stable system for transient packaging of retroviruses , 2000, Gene Therapy.
[32] S. Sebti,et al. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines , 1997, Oncogene.
[33] R. Pearson,et al. The principal target of rapamycin‐induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. , 1995, The EMBO journal.
[34] R L Smith,et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. , 1993, Science.
[35] H. Hirsch,et al. Mast cells sensitive to v-H-ras transformation are hyperinducible for interleukin 3 expression and have lost tumor-suppressor activity. , 1992, Oncogene.